Home › Neuroblastoma › South Carolina › Charleston
Neuroblastoma clinical trials in Charleston, SC
4 studies for Neuroblastoma are looking for participants at sites in and around Charleston (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
RecruitingPhase 3
- Medical University of South Carolina, Charleston
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
RecruitingPhase 2
- Medical University of South Carolina, Charleston
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
RecruitingPhase 3
- Medical University of South Carolina, Charleston
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
RecruitingPhase 2
- Medical University of South Carolina, Charleston
About Neuroblastoma
Neuroblastoma is a cancer in nerve tissue in the adrenal gland, neck, chest, or spinal cord. It often affects young children. Read about treatments.
More about Neuroblastoma on MedlinePlus
Neuroblastoma trials in other cities
- Boston, MA13 studies
- Washington, DC11 studies
- New York City, NY10 studies
- St. Louis, MO9 studies
- Dallas, TX9 studies
- Memphis, TN9 studies
- Philadelphia, PA9 studies
- Birmingham, AL8 studies
- Hartford, CT8 studies
- Aurora, CO8 studies
- Minneapolis, MN8 studies
- Miami, FL7 studies
Other studies in Charleston
- Depression19 studies
- Stroke18 studies
- Heart Failure18 studies
- Non-Small Cell Lung Cancer16 studies
- Post-Traumatic Stress Disorder16 studies
- Cardiovascular Disease15 studies
- Prostate Cancer15 studies
- Cancer (all types)14 studies
- Head and Neck Squamous Cell Carcinoma14 studies
- Parkinson's Disease13 studies
- Interstitial Lung Diseases13 studies
- Breast Cancer12 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.